Please stay tuned for important disclosure information at the conclusion of this episode.

Here's what's ahead on this week's investing insights.

Recent bank failures have rocked Wall Street, why investors should pay attention to this banking crisis.

Plus, Pfizer makes a $43 billion deal as it prepares for several drugs to lose their patents,

and a growth opportunity could boost the sector better known for investment income. A Morning Star strategist will join the podcast

and explain how. This is Investing Insights. Welcome to Investing Insights. I'm your host, Ivana Hampton, and let's get started with a look at the Morning Star headlines.

Pfizer's newest acquisition may help put investors at ease about upcoming patent losses.

The Farmer Giant says it's buying cancer drug developer, C-Gen, for almost $43 billion.

The deal will likely close in late 2023 or early

2024. Morningstar doesn't see the purchase creating any value for Pfizer. However, it could

help the market get more comfortable with Pfizer working through major patent losses on several

drugs. The list includes cardiovascular drug eloquist and oncology drug eyebrows. If C-Gens' pipeline of early

and mid-stage drugs developed better than Morningstar's expectations, this could benefit Pfizer.

Morningstar expects the acquisition to bring in close to $8 billion of revenue by 2030. That's less than Pfizer's outlook.

C-GEN's already approved cancer drugs appear to have strong growth potential.

And the deal doesn't have a major impact on Morningstar's $48 estimate of what Pfizer's stock is worth.

The shares look undervalued.

Adidas reported weak sales and a massive loss in 2022's fourth quarter.

The German sportswear company's new CEO announced the results during an earnings call.

They were expected and in line with Morningstar's estimates.

The demise of Adidas deal with Yeezy, the fashion brand of Yeh, caused much of the losses.

The designer and rapper formerly known as Kanye West made anti-Semitic remarks.

...